Flow Reversal Versus Filter Protection

Author:

de Castro-Afonso Luis Henrique1,Abud Lucas Giansante1,Rolo Jaicer Gonçalves1,dos Santos Antônio Carlos1,de Oliveira Lívia1,Barreira Clara Monteiro Antunes1,Velasco Tonicarlo Rodrigues1,Pontes-Neto Octávio Marques1,Abud Daniel Giansante1

Affiliation:

1. From the Division of Interventional Neuroradiology (L.H.d.C.-A., L.d.O., D.G.A.), Division of Neuroradiology (L.G.A., J.G.R., A.C.d.S.), and Division of Neurology (C.M.A.B., T.R.V., O.M.P.-N.), Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.

Abstract

Background— Carotid artery stenting (CAS) has become an alternative treatment for patients presenting symptomatic carotid artery stenosis. The improvement in clinical outcomes with CAS has been associated with the development of embolic protection devices. The trial aim is to compare flow reversal versus filter protection during CAS through femoral access. Methods and Results— Patients were randomly enrolled in CAS using flow reversal or filter protection. The primary end points were the incidence, number, and size of new ischemic brain lesions after CAS. The secondary end points included major adverse cardiac and cerebrovascular events, transient ischemic attack, and definitive ischemic brain lesions on fluid-attenuated inversion recovery magnetic resonance image at a 3-month follow-up. Ischemic brain lesions were assessed by a 3T magnetic resonance image. Neurological outcomes were evaluated by means of the National Institutes of Health Stroke Scale and the modified Rankin Scale (mRS). Forty consecutive patients were randomly assigned. Compared with flow reversal (n=21), filter protection (n=19) resulted in a significant reduction in the incidence (15.8% versus 47.6%, P =0.03), number (0.73 versus 2.6, P =0.05), and size (0.81 versus 2.23 mm, P =0.05) of new ischemic brain lesions. Two patients, 1 from each group, presented transient ischemic attack at 3-month follow-up. There were no major adverse cardiac and cerebrovascular events in the hospital or at 3-month follow-up. Conclusions— In this small sample size trial, filter protection was more effective than flow reversal in reducing ischemic brain lesions during CAS through femoral approach. Clinical Trial Registration— URL: http://portal2.saude.gov.br/sisnep/ . Unique identifier: 0538.0.004.000-10.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3